mediStat Pharmacy Announces Voluntary Registration as the first FDA 503B Outsourcing Facility in Alabama

Share Article

mediStat Specialized Pharmacy today announced it has voluntarily registered with the US Food and Drug Administration (FDA) as a Human Drug Compounding Outsourcing Facility under section 503B of the Federal Food, Drug, and Cosmetic (FD&C) Act.

mediStat Specialized Pharmacy today announced it has voluntarily registered with the US Food and Drug Administration (FDA) as a Human Drug Compounding Outsourcing Facility under section 503B of the Federal Food, Drug, and Cosmetic (FD&C) Act. This new designation was created in November 2013 when President Obama signed Title 1 of the Drug Quality and Security Act (DQSA) referred to as the Compounding Quality Act into law.

The law, which calls for large-scale entities in the compounding industry to voluntarily register with the FDA and comply with guidelines, under the section 503B of the FD&C Act, has been recognized for the potential to improve patient safety as well as the protection that DQSA also affords hospitals/health systems and other healthcare providers.

As an 503B outsourcing facility, mediStat will become the first facility in the State of Alabama to be listed on the FDA’s approved list of compounding pharmacies. mediStat will therefore be able to compound and distribute medications to hospitals and clinics without patient-specific prescriptions provided that all requirements of Section 503B are met. With this new designation mediStat is implementing guidelines provided under Current Good Manufacturing Practice (CGMP) regulations. The CGMP will ensure that higher standards of quality and safety are met.

The fundamental regulation prior to the new Compounding Quality Act was USP 797. This regulation was used to govern sterile compounding pharmacies and guidance was provided by state boards of pharmacy. Due to the fungal meningitis outbreak in October 2012 caused by poor sterility assurance at New England Compounding Center in Massachusetts, federal legislators passed the new law. This law will expand the role of the FDA in providing guidance for compounding pharmacies.

Registration with the FDA is not mandatory under the current guidelines. If a compounding pharmacy is not registered as an outsourcing facility they will no longer be able to supply “office use” medications to clinics, hospitals and physician offices. mediStat prides itself on being one of the first compounding pharmacies to voluntarily register with the FDA as a 503B Outsourcing facility and is committed to working together with the FDA and state authorities to supply patients with safe and high-quality drug products.

Compounding pharmacies are instrumental in the health and well-being of millions of individuals across the United States. Pharmacy compounding is the art and science of preparing medications for individual patients that are in need of a drug that is not readily available through traditional means.

About mediStat Specialized Pharmacy
mediStat is a full service pharmacy located in Foley, Alabama just north of the beautiful Gulf Shores Beaches. mediStat specializes in sterile injectables, hormone replacement therapy, topical pain creams, skin care products and other highly specialized medications to meet individual needs of each and every patient.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rachel Kaiser
medistat
+1 251.424.1092
Email >

Rachel Kaiser
MediStat
Like >
Visit website

Media